trending Market Intelligence /marketintelligence/en/news-insights/trending/tr3bikckzwjcuz0bclqg1g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Medtronic's drug-coated balloons snag US FDA approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Medtronic's drug-coated balloons snag US FDA approval

Two versions of Medtronic PLC's IN.PACT Admiral balloons to treat lesions in blocked arteries have received approval from the U.S. Food and Drug Administration.

The Dublin, Ireland company's drug-coated balloons can be used to treat 200-millimeter and 250-millimeter lesions in patients with peripheral artery disease, a buildup of fatty deposits that lead to narrowed arteries and less blood flow.

The FDA approved a 360mm version of the device in April.

In all three cases, the balloons are used in the superficial femoral artery, the main artery running through the leg and an important pathway for oxygenated blood to flow through the limb.